C-RAD and Mevion Release Integration for Improved Treatment Quality in Proton Therapy
C-RAD and Mevion Medical Systemsâ announced today the integration between the C-RAD Catalyst PT™ and the MEVION S250i Proton Therapy System ® . The union of both products supports a seamless workflow with uninterrupted patient surface tracking monitoring from setup through treatment.
C-RAD offers a specific version of its Catalyst System for use in proton and particle therapy - the Catalyst PT, based on the patented Catalyst technology and software.
Maastro Proton Therapy, equipped with the MEVION 250i Proton Therapy System, and C-RAD announced a strategic agreement in 2018 to install the Catalyst PT at the Center. C-RAD and Mevion co-developed a solution based on both companies’ products that allows a high level of integration to enhance user comfort and patient safety.
Guided by the expertise and requirements of Maastro Proton Therapy, the two industry partners focused on developing the interface required to support a seamless workflow, including automatic patient position correction and monitoring throughout the entire treatment process.
Tina Yu, chief executive officer of Mevion Medical Systems, says:
“In keeping with Mevion's commitment to providing innovative products and services, we are proud to partner with C-RAD to offer the most advanced and fully integrated proton patient positioning platform to our customers.”
The installation of the Catalyst PT at Maastro Proton Therapy was commissioned over the past month and has been released for clinical operation beginning this August. Maastro Proton Therapy will be deploying the Catalyst PT especially for thoracic tumor indications treated on the Mevion system.
Geert Bosmans, managing director of Maastro Proton Therapy says:
“To provide our patients with an improved high-quality treatment plan we installed the C-RAD surface tracking system in our center. We will use it to accurately position and continuously monitor our patients during treatment for increased high precision radiation therapy.”
The Catalyst PT system is now available to current and future Mevion customers.
“Accurate patient positioning before and monitoring during treatment is crucial in high precision radiation therapy. This development is driving the interest for our leading surface tracking solutions.” says Tim Thurn, CEO and President of C-RAD AB, “User experience and workflow optimization is becoming increasingly important for our customers. C-RAD’s objective has always been to define the benchmark in usability and workflow integration. With this project, C-RAD and Mevion stepped up to mark the new standard.”
About Maastro Proton Therapy:
The Maastro Proton Therapy started treating patients with protons in February 2019. It is the first Mevion system in Europe and because of the compact Mevion technology is being fully integrated into an existing radiotherapy center, Maastricht Radiation Oncology (Maastro). ( www.maastro.nl/protonentherapie ).
C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are integrated. C-RAD AB is listed on NASDAQ Stockholm.
For more information on C-RAD, please visit http://www.c-rad.com
About Mevion Medical Systemsâ
Mevion Medical Systems, Inc. is the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients. Mevion is based in Littleton, Massachusetts, with a presence in Europe and China. For more information, please visit www.mevion.com.
For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email firstname.lastname@example.org
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
KALLELSE TILL ÅRSSTÄMMA I HOYLU AB (PUBL)26.5.2020 22:30:00 CEST | Pressemelding
KALLELSE TILL ÅRSSTÄMMA I HOYLU AB (PUBL) Aktieägarna i Hoylu AB (publ), org. nr 559084-6381 ("Bolaget") kallas härmed till Bolagets årsstämma torsdagen den 25 juni 2020, kl. 09.00 hos Eversheds Sutherland Advokatbyrå på Strandvägen 1 i Stockholm. Inregistrering inleds kl. 08.45. INFORMATION MED ANLEDNING AV COVID-19 Med anledning av COVID-19 kommer Bolaget att vidta vissa försiktighetsåtgärder inför årsstämman. För att minska risken för smittspridning kommer ingen förtäring eller dryck att erbjudas. Styrelsemedlemmar och Bolagets ledning kommer i möjligaste mån att närvara via elektronisk uppkoppling. Aktieägarna har möjlighet att närvara via ombud. DELTAGANDE En aktieägare som vill delta på årsstämman ska: vara införd i den av Euroclear Sweden AB förda aktieboken senast torsdagen den 18 juni 2020, och anmäla sitt deltagande senast torsdagen den 18 juni 2020, helst före kl. 16.00. Anmälan att delta på årsstämman ska ske via e-post till email@example.com, via post till to Hoylu AB
NOTICE TO ATTEND THE ANNUAL GENERAL MEETING OF HOYLU AB (PUBL)26.5.2020 22:30:00 CEST | Press release
N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the Annual General Meeting in Hoylu AB (publ), and in case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. NOTICE TO ATTEND THE ANNUAL GENERAL MEETING OF HOYLU AB (PUBL) The shareholders of Hoylu AB (publ), reg. no 559084-6381 (the “Company”) are hereby summoned to attend the annual general meeting held at 09:00 (CEST) on Thursday 25 June 2020 at the premises of Eversheds Sutherland Advokatbyrå located at Strandvägen 1, Stockholm, Sweden. Registration begins at 08.45 (CEST). INFORMATION RELATED TO THE CORONA VIRUS To minimise the risk of spreading the corona virus, no food and beverages will be served at the AGM. Participation of board members and company management will be restricted to online where possible. Shareholders who so desire can attend via a representative. NOTIFICATION OF PARTICIPATION ETC. Shareholders who wish to a
Results of the annual general meeting of ENR Russia Invest SA26.5.2020 19:10:00 CEST | Press release
Press Release Geneva, 26 May 2020 Results of the annual general meeting of ENR Russia Invest SA All resolutions proposed by the board of directors (“Board”) of ENR Russia Invest SA (“Company”) were unanimously approved at the Company’s annual general meeting held on 26 May 2020, being: Approval of 2019 annual report and financial statements for the year ended 31 December 2019 of both the group and the Company and the carrying forward of CHF 234'656 of retained losses.Discharge of all members of the Board for the 2019 financial year.Re-election for one year of Dr. Walter Fetscherin and Mr. Gustav Stenbolt to the Board, with Mr. Gustav Stenbolt as Company chairman (each for a term of office up to the next annual general meeting).Election of Dr. Walter Fetscherin and Mr. Gustav Stenbolt to the Company’s remuneration committee.Election of ZELLWEGER & MASSROURI as independent shareholder representative for the 2021 annual general meeting.Re-election of BDO SA, Geneve as the Company and grou
Saniona meddelar utfall i optionsinlösen26.5.2020 18:15:00 CEST | Pressemelding
PRESSMEDDELANDE 26 maj 2020 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelade idag utfallet i inlösen av teckningsoptioner av serie TO 1, vilka emitterades i samband med Sanionas företrädesemission och riktade emission under det första kvartalet 2020. Under perioden 11 – 25 maj 2020 har innehavare av teckningsoptioner av serie TO 1 kunnat teckna aktier med stöd av teckningsoptioner. Totalt nyttjades 970 797 teckningsoptioner av serie TO 1, vilket motsvarar en nyttjandegrad om 65,61 procent. Saniona tillförs därmed cirka 24,3 MSEK före emissionskostnader, vilka beräknas uppgå till cirka 0,4 MSEK. Antal aktier och aktiekapital Saniona tillförs cirka 24,3 MSEK före emissionskostnader. Emissionskostnaderna beräknas uppgå till cirka 0,4 MSEK. När de nya aktierna har registrerats hos Bolagsverket kommer antalet aktier i Saniona uppgå till 30 383 316 stycken och aktiekapitalet uppgå till 1 519 165,80 SEK. ”Vi är tacksamma fö
Saniona announces outcome of warrant exercise26.5.2020 18:15:00 CEST | Press release
PRESS RELEASE May 26, 2020 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, announced today the outcome in the exercise of warrants of series TO 1, that was issued in connection with Saniona’s rights issue and directed issue in the first quarter of 2020. During the period May 11th – 25th, 2020, holders of warrants of series TO 1 had the right to subscribe for new shares, by exercise of warrants. In total, 970,797 warrants of series TO 1 were exercised, corresponding to a subscription rate of 65.61 percent. Saniona will thereby receive proceeds of approx. SEK 24.3 million, before issue costs, which amount to approx. SEK 0.4 million. Number of shares and share capital Saniona will receive proceeds of approx. SEK 24.3 million, before issue costs. Issue costs amount to approx. SEK 0.4 million. When the new shares have been registered with the Swedish Companies Registration Office (“Bolagsverket”), the total number of shares in Saniona will amount
Intervest Offices & Warehouses: Result of the optional dividend in shares for financial year 201926.5.2020 18:00:00 CEST | Press release
Shareholders opted for 61,6% of the shares for the optional dividendShareholders’ equity strengthened by € 16,3 million The shareholders of regulated real estate company Intervest Offices & Warehouses opted for 61,6% of their shares entitled to dividend for a contribution of their dividend rights in return for new shares instead of payment of the dividend in cash. Attachment Result optional dividend